QIANG CHENG

Dr. QIANG CHENG


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
QCQIANG CHENG
QIANG CHENG
Tuo WeiTuo Wei
Tuo Wei
LFLukas Farbiak
Lukas Farbiak
LJLindsay T. Johnson
Lindsay T. Johnson
SDSean A. Dilliard
Sean A. Dilliard
DSDaniel Siegwart
Daniel Siegwart

21 December 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SDSean A. Dilliard
Sean A. Dilliard
QCQIANG CHENG
QIANG CHENG
DSDaniel Siegwart
Daniel Siegwart
Lipid nanoparticles (LNPs) are a clinically mature technology for the delivery of genetic medicines but have limited therapeutic applications due to liver accumulation. Recently, our laboratory developed selective organ targeting (SORT) nanoparticles that expand the therapeutic applications of genetic medicines by enabling delivery of messenger RNA (mRNA) and gene editing systems to non-liver tissues. SORT nanoparticles include a supplemental SORT molecule whose chemical structure determines the LNP’s tissue-specific activity. To understand how SORT nanoparticles surpass the delivery barrier of liver hepatocyte accumulation, we studied the mechanistic factors which define their organ-targeting properties. We discovered that the chemical nature of the added SORT molecule controlled biodistribution, global/apparent pKa, and serum protein interactions of SORT nanoparticles. Additionally, we provide evidence for an endogenous targeting mechanism whereby organ targeting occurs via 1) desorption of poly(ethylene glycol) lipids from the LNP surface, 2) binding of distinct proteins to the nanoparticle surface because of recognition of exposed SORT molecules, and 3) subsequent interactions between surface-bound proteins and cognate receptors highly expressed in specific tissues. These findings establish a crucial link between the molecular composition of SORT nanoparticles and their unique and precise organ-targeting properties and suggest that the recruitment of specific proteins to a nanoparticle’s surface can enable drug delivery beyond the liver. Significance Liver accumulation represents a significant barrier in the development of therapeutically efficacious nanoparticle drug delivery systems. Using a series of lipid nanoparticles with distinct organ-targeting properties, we provide evidence for a plausible mechanism of action for nanoparticle delivery to non-liver tissues. Following intravenous injection, specific proteins in the blood are recruited to the nanoparticle’s surface based on its molecular composition and they endow it with a unique biological identity that governs its ultimate fate in the body. An innovative paradigm emerges from this mechanistic understanding of nanoparticle delivery—endogenous targeting—wherein the molecular composition of a nanoparticle is rationally engineered to interact with specific proteins in the blood to overcome liver accumulation and to target specific organs.

4 February 2021 in Nature Materials
Verified
Journal Article
Closed access
PDF file
SLShuai Liu
Shuai Liu
QCQIANG CHENG
QIANG CHENG
Tuo WeiTuo Wei
Tuo Wei
XYXueliang Yu
Xueliang Yu
LJLindsay T. Johnson
Lindsay T. Johnson
DSDaniel Siegwart
Daniel Siegwart

26 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Tuo WeiTuo Wei
Tuo Wei
QCQIANG CHENG
QIANG CHENG
YMYi-Li Min
Yi-Li Min
EOEric N. Olson
Eric N. Olson
DSDaniel Siegwart
Daniel Siegwart
CRISPR-Cas9 has emerged as a powerful technology that relies on Cas9/sgRNA ribonucleoprotein complexes (RNPs) to target and edit DNA. However, many therapeutic targets cannot currently be accessed due to the lack of carriers that can deliver RNPs systemically. Here, we report a generalizable methodology that allows engineering of modified lipid nanoparticles to efficiently deliver RNPs into cells and edit tissues including muscle, brain, liver, and lungs. Intravenous injection facilitated tissue-specific, multiplexed editing of six genes in mouse lungs. High carrier potency was leveraged to create organ-specific cancer models in livers and lungs of mice though facile knockout of multiple genes. The developed carriers were also able to deliver RNPs to restore dystrophin expression in DMD mice and significantly decrease serum PCSK9 level in C57BL/6 mice. Application of this generalizable strategy will facilitate broad nanoparticle development for a variety of disease targets amenable to protein delivery and precise gene correction approaches.

1 November 2023 in Advanced Materials
Verified
Journal Article
Closed access
YZYan Zong
Yan Zong
YLYi Lin
Yi Lin
Tuo WeiTuo Wei
Tuo Wei
QCQIANG CHENG
QIANG CHENG

23 February 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Tuo WeiTuo Wei
Tuo Wei
CCChao Chen
Chao Chen
JLJuan Liu
Juan Liu
CLCheng Liu
Cheng Liu
PPPAOLA POSOCCO
PAOLA POSOCCO
LPLing Peng
Ling Peng
Significance: Nanotechnology-based drug delivery is expected to bring new hope for cancer treatment by enhancing anticancer drug efficacy, overcoming drug resistance, and reducing drug toxicity. In this respect, we developed an innovative drug delivery system based on a self-assembling amphiphilic dendrimer, which can generate supramolecular nanomicelles with large void space in their core to encapsulate anticancer drugs with high loading capacity. The resulting drug-encapsulated nanomicelles can effectively enhance drug potency and combat drug resistance by promoting cellular uptake and decreasing efflux of the anticancer drug. Moreover, this drug delivery system can significantly reduce the systemic toxicity of the free drug. The present study illustrates a successful example of how advances in dendrimer nanotechnology can be advantageously implemented to foster therapeutic perspectives.